Related references
Note: Only part of the references are listed.Nanoparticle formulations of histone deacetylase inhibitors for effective chemoradiotherapy in solid tumors
Edina C. Wang et al.
BIOMATERIALS (2015)
Systemic and Targeted Therapy for Biliary Tract Tumors and Primary Liver Tumors
Melanie Byrne Thomas
SURGICAL ONCOLOGY CLINICS OF NORTH AMERICA (2014)
Pathogenesis, Diagnosis, and Management of Cholangiocarcinoma
Sumera Rizvi et al.
GASTROENTEROLOGY (2013)
Evaluation of safety, pharmacokinetics, and efficacy of vorinostat, a histone deacetylase inhibitor, in the treatment of gastrointestinal (GI) cancer in a phase I clinical trial
Toshihiko Doi et al.
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY (2013)
Histone deacetylase inhibitors suppress mutant p53 transcription via histone deacetylase 8
W. Yan et al.
ONCOGENE (2013)
Histone acetyltransferases and deacetylases: molecular and clinical implications to gastrointestinal carcinogenesis
Wei-Jian Sun et al.
ACTA BIOCHIMICA ET BIOPHYSICA SINICA (2012)
Tumor vasculature targeting following co-delivery of heparin-taurocholate conjugate and suberoylanilide hydroxamic acid using cationic nanolipoplex
Ji-young Kim et al.
BIOMATERIALS (2012)
Phase I-II study of vorinostat plus paclitaxel and bevacizumab in metastatic breast cancer: evidence for vorinostat-induced tubulin acetylation and Hsp90 inhibition in vivo
B. Ramaswamy et al.
BREAST CANCER RESEARCH AND TREATMENT (2012)
Anti-tumor activity of all-trans retinoic acid-incorporated glycol chitosan nanoparticles against HuCC-T1 human cholangiocarcinoma cells
Kyu-Don Chung et al.
INTERNATIONAL JOURNAL OF PHARMACEUTICS (2012)
Vorinostat with sustained exposure and high solubility in poly(ethylene glycol)-b-poly(dl-lactic acid) micelle nanocarriers: Characterization and effects on pharmacokinetics in rat serum and urine
Elham A. Mohamed et al.
JOURNAL OF PHARMACEUTICAL SCIENCES (2012)
Phase I trial of vorinostat combined with bevacizumab and CPT-11 in recurrent glioblastoma
Prakash Chinnaiyan et al.
NEURO-ONCOLOGY (2012)
Down-Regulated Expression of HSP70 in Correlation with Clinicopathology of Cholangiocarcinoma
Sirintip Boonjaraspinyo et al.
PATHOLOGY & ONCOLOGY RESEARCH (2012)
SAHA Inhibits the Growth of Colon Tumors by Decreasing Histone Deacetylase and the Expression of Cyclin D1 and Survivin
Jong-Shiaw Jin et al.
PATHOLOGY & ONCOLOGY RESEARCH (2012)
Biodegradable Thermosensitive Hydrogel for SAHA and DDP Delivery: Therapeutic Effects on Oral Squamous Cell Carcinoma Xenografts
Jing Li et al.
PLOS ONE (2012)
Role of histone deacetylase expression in intrahepatic cholangiocarcinoma
Yuji Morine et al.
SURGERY (2012)
Review article: surgical, neo-adjuvant and adjuvant management strategies in biliary tract cancer
J. R. A. Skipworth et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2011)
The controlled photoactivity of nanoparticles derived from ionic interactions between a water soluble polymeric photosensitizer and polysaccharide quencher
Wooram Park et al.
BIOMATERIALS (2011)
SAHA shows preferential cytotoxicity in mutant p53 cancer cells by destabilizing mutant p53 through inhibition of the HDAC6-Hsp90 chaperone axis
D. Li et al.
CELL DEATH AND DIFFERENTIATION (2011)
Gene Expression Signature Analysis Identifies Vorinostat as a Candidate Therapy for Gastric Cancer
Sofie Claerhout et al.
PLOS ONE (2011)
Polylactide (PLA)-based amphiphilic block copolymers: synthesis, self-assembly, and biomedical applications
Jung Kwon Oh
SOFT MATTER (2011)
Autophagy potentiates the anti-cancer effects of the histone deacetylase inhibitors in hepatocellular carcinoma
Yuan-Ling Liu et al.
AUTOPHAGY (2010)
Hybrid liposomes inhibit the growth of Cholangiocarcinoma by induction of cell cycle arrest in G1 phase
Tomomi Towata et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2010)
Vorinostat synergises with capecitabine through upregulation of thymidine phosphorylase
E. Di Gennaro et al.
BRITISH JOURNAL OF CANCER (2010)
Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer.
Juan Valle et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Radiotherapy and Chemotherapy as Therapeutic Strategies in Extrahepatic Biliary Duct Carcinoma
Thomas B. Brunner et al.
STRAHLENTHERAPIE UND ONKOLOGIE (2010)
HDAC expression and clinical prognosis in human malignancies
Wilko Weichert
CANCER LETTERS (2009)
Association of patterns of class I histone deacetylase expression with patient prognosis in gastric cancer:: a retrospective analysis
Wilko Weichert et al.
LANCET ONCOLOGY (2008)
Area of paradoxical signal drop after the administration of superparamagnetic iron oxide on the T2-weighted image of a patient with lymphangitic metastasis of the liver
Youkyung Lee et al.
MAGNETIC RESONANCE IMAGING (2008)
Histone deacetylase inhibitors: molecular mechanisms of action
W. S. Xu et al.
ONCOGENE (2007)
Cancer biology: mechanism of antitumour action of vorinostat (suberoylanilide hydroxamic acid), a novel histone deacetylase inhibitor
V. M. Richon
BRITISH JOURNAL OF CANCER (2006)
A Phase II study of gemcitabine and cisplatin in advanced biliary tract cancer
ST Kim et al.
CANCER (2006)
Suberoylanilide hydroxamic acid potentiates apoptosis, inhibits invasion, and abolishes osteoclastogenesis by suppressing nuclear factor-κB activation
Y Takada et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2006)
Exploiting the enhanced permeability and retention effect for tumor targeting
Arun K. Iyer et al.
DRUG DISCOVERY TODAY (2006)
Histone deacetylase inhibitors, anticancerous mechanism and therapy for gastrointestinal cancers
JY Fang
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY (2005)
Cholangiocarcinoma: Molecular targeting strategies for chemoprevention and therapy
AE Sirica
HEPATOLOGY (2005)
Histone acetylation regulates p21WAF1 expression in human colon cancer cell lines
Ying-Xuan Chen et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2004)
Cholangiocarcinoma: Morphologic classification according to growth pattern and imaging findings
JH Lim
AMERICAN JOURNAL OF ROENTGENOLOGY (2003)
Changing international trends in mortality rates for liver, biliary and pancreatic tumours
SA Khan et al.
JOURNAL OF HEPATOLOGY (2002)
Histone deacetylase inhibitors in cancer treatment
DM Vigushin et al.
ANTI-CANCER DRUGS (2002)
MR imaging of intrahepatic cholangiocarcinoma: Use of ferumoxides for lesion localization and extension
HJV Braga et al.
AMERICAN JOURNAL OF ROENTGENOLOGY (2001)
Mechanisms of suberoylanilide hydroxamic acid inhibition of mammary cell growth
TK Said et al.
BREAST CANCER RESEARCH (2001)
Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review
H Maeda et al.
JOURNAL OF CONTROLLED RELEASE (2000)
Share Paper
